File Download

There are no files associated with this item.

Supplementary

Conference Paper: First interim results from KEYNOTE-495/KeyImPaCT, a randomized, phase 2, biomarker-directed trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC)

TitleFirst interim results from KEYNOTE-495/KeyImPaCT, a randomized, phase 2, biomarker-directed trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC)
Authors
Issue Date2019
Citation
ESMO 2019, Barcelona, Spain (27 Sept - Oct 1 2019) How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/279578

 

DC FieldValueLanguage
dc.contributor.authorGutierrez, M-
dc.contributor.authorLam, W-S-
dc.contributor.authorHellmann, MD-
dc.contributor.authorGubens, CA-
dc.contributor.authorTan, DSW-
dc.contributor.authorFelip, E-
dc.contributor.authorChiu, WYJ-
dc.contributor.authorLee, JS-
dc.contributor.authorYang, JCH-
dc.contributor.authorGaron, EB-
dc.date.accessioned2019-11-01T07:20:02Z-
dc.date.available2019-11-01T07:20:02Z-
dc.date.issued2019-
dc.identifier.citationESMO 2019, Barcelona, Spain (27 Sept - Oct 1 2019)-
dc.identifier.urihttp://hdl.handle.net/10722/279578-
dc.languageeng-
dc.relation.ispartofESMO 2019, Barcelona, Spain (27 Sept - Oct 1 2019)-
dc.titleFirst interim results from KEYNOTE-495/KeyImPaCT, a randomized, phase 2, biomarker-directed trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC) -
dc.typeConference_Paper-
dc.identifier.emailChiu, WYJ: jwychiu@hku.hk-
dc.identifier.authorityChiu, WYJ=rp01917-
dc.identifier.hkuros308515-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats